摘要
目的评价新活素治疗充血性心力衰竭(CHF)的疗效及其不良反应。方法治疗组48例,给予新活素治疗;对照组52例,给予硝普钠治疗。观察两组用药前后生命体征、呼吸困难程度及相关血流动力学指标的变化。结果两组比较,在改善呼吸困难程度等临床症状及左室射血分数方面差异显著(P<0.05);发生与用药有关的不良反应治疗组1例,对照组7例,两组比较差异显著(P<0.01)。结论新活素治疗CHF疗效显著,不良反应发生率低。
Objective To evaluate efficacy and safety of Xinhuosu in treatment of congestive heart failure （CHF）. Methods 100 patients characterized of congestive heart failure were enrolled in this study. The patients were randomly allocated to treatment group and control group. 48 cases of treatment group were treated with Xinhuosu and 52 cases of the control group were treated with sodium nitroprusside. Blood pressure, heart rate, dyspnea grade, symptoms and signs were evaluated. Results Improvements of symptom and ejection fraction were more significant in treatment group compared to control group （P〈0.05）. Drug-related adverse events in treatment group was significantly lower than that in control group （P〈0.01）. Conclusions Xinhuosu is superior to nitroglycerin in improving clinical symptoms such as dyspnea and ejection fraction on congestive heart failure.
出处
《西部医学》
2010年第1期112-114,共3页
Medical Journal of West China
基金
绵阳市应用技术研究与开发基金项目(No:07S006-6)
关键词
新活素
硝普钠
充血性心力衰竭
Congestive heart failure
Xinhuosu
Sodium nitroprusside
